Articles tagged with Molecular Imaging
A new study found that combining molecular breast imaging (MBI) and digital breast tomosynthesis (DBT) increases invasive cancer detection while moderately increasing recall rates. MBI detected an additional 6.7 cancers per 1,000 screenings in women with dense breasts.
A new PET tracer, 64Cu-NOTA-EV-F(ab′2), has been developed for same-day imaging of triple-negative breast and urothelial bladder cancers. The tracer exhibits rapid tumor accumulation and high specificity in nectin-4 positive tumors, enabling accurate non-invasive visualization of this protein.
Faster PET scans show promise for detecting liver inflammation and metabolic dysfunction-associated steatohepatitis. An AI tool combines multiple PET scans to integrate data from different tracers, improving disease insights. New imaging techniques enhance breast cancer surgery and predict recovery after heart attack.
A new targeted radiation approach has achieved a near-complete response in three patients with solitary fibrous tumor (SFT), a rare and aggressive form of cancer. The therapy significantly reduced cancer activity and provided symptom relief, highlighting its potential as a treatment option.
New PET imaging agents show promise for detecting thyroid and neuroendocrine tumors, as well as reversing fibrosis in the heart. Researchers also explored tau PET scans for Alzheimer's detection and SSTR PET/CT for meningioma diagnosis. These advancements hold potential for improving cancer treatment and patient outcomes.
Researchers developed a new PET tracer that effectively identifies synapse loss in the spinal cord and brain after spinal cord injury. The study found reduced uptake of the tracer at the injury site and in the amygdala and cerebellum, suggesting potential for diagnosing and monitoring spinal cord injuries.
Researchers have developed new PET tracers to monitor immune responses and inflammation beyond the lungs throughout the course of SARS-CoV-2 infection. These breakthroughs offer a new way to visualize changes in lymph nodes, spleen, and bone marrow, supporting faster and more comprehensive imaging.
Researchers mapped the surface envelope glycoprotein of human endogenous retroviruses, opening doors to new diagnostic and therapeutic opportunities. The study revealed specific antibodies that target the viral proteins, potentially leading to new cancer immunotherapies and treatments for autoimmune diseases.
Researchers have published three studies using new imaging approaches to detect and treat various types of cancer. These advancements include positronium lifetime tomography for sharper scans, targeted radiotherapy for sarcoma patients, and biomarkers for endometrial cancer diagnosis.
The latest issue of SLAS Technology highlights significant advancements in biomedicine and diagnostics, with AI-powered tools achieving 99.9% accuracy in detecting monkeypox. Additionally, the journal showcases innovative lab technologies, including multi-camera zebrafish assays and infection-proof titanium implants.
A new technique uses a topical fluorescent molecular contrast agent to detect basal cell carcinoma, which can be done non-invasively in as little as five minutes. The technique shows promise for improving diagnostic accuracy and reducing unnecessary biopsies.
Recent studies have shown promising results for triple-targeted cancer therapy, new PET imaging tracers tracking immune activation, and reducing PET scan doses while maintaining diagnostic accuracy. These advancements hold promise for improving cancer treatment outcomes and precision medicine.
A new study from Denmark shows that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to those who do not. This research confirms that PSMA PET/CT is a valuable tool for identifying patients likely to benefit from salvage radiotherapy, potentially ...
The Global Radiopharmaceutical Trial Finder, a new AI-powered platform, helps researchers, clinicians, and patients discover clinical trials for life-changing nuclear medicine procedures. The platform uses real-time global trials data and streamlines the trial participation process.
Researchers at MIT have developed a new microscope system that can visualize metabolic and neuronal activity in brain tissues with unprecedented depth and precision. The system uses sound waves to detect molecular activity, enabling the imaging of individual cells in dense brain tissue.
Researchers developed a radiotracer targeting CD24 protein on liver tumor cells, accurately detecting tumors in mice. PSMA PET/CT scans also tracked prostate cancer spread in patients, predicting shorter survival for those with interlesional progression.
A first-in-human study found that naloxone reduces opioid receptor availability by 40-50 percent in brain regions, but shows a greater reduction in women compared to men. This suggests sex-based differences in how men and women respond to opioid overdose treatments.
Researchers at the University of Illinois found that benign and cancerous breast calcifications have unique structures and formation processes. The study provides a new classification scheme and opens the possibility of treating benign calcifications using certain drugs.
A new study found that long COVID patients with abnormal cardiopulmonary PET/MR findings are at a higher risk of developing heart and lung diseases. The study included 98 patients with persistent cardiopulmonary symptoms after initial COVID infection and showed significant abnormalities in both PET/MRI and dual-energy CT scans.
Researchers at Vanderbilt University have generated a high-resolution metabolic map of how cells process glucose, revealing a hidden world where organelles and molecular complexes collaborate. The study provides insights into an organizational framework that can be used to study disruptions in diseases like diabetes, obesity, and cancer.
The Society of Nuclear Medicine and Molecular Imaging's Annual Meeting featured over 120 continuing education sessions on innovations in oncology, neurology, and cardiology. The meeting also showcased cutting-edge technology, including AI, theranostics, and novel imaging probes.
Jean-Luc C. Urbain has been named president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), aiming to integrate radiopharmaceutical theranostics into clinical practice. As president, he plans to prioritize research, education, and patient safety to benefit patients worldwide.
A study found that modifiable risk factors like education, BMI, and hypertension can slow down the spread of Alzheimer's tau tangles. The research suggests that modifying these risk factors can help delay disease progression.
Heather Jacene, MD, has been elected as the new president-elect of SNMMI, with a focus on strengthening the organization and promoting nuclear medicine. She aims to create opportunities for member participation and multidisciplinary collaborations, while raising awareness of nuclear medicine's value to clinical colleagues and patients.
Dr. Gary Ulaner has been elected vice president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), committed to advancing nuclear medicine research and expanding educational activities for professionals. As part of his role, he aims to drive growth and funding for training new radiochemistry and physics professionals.
A novel PET imaging approach can accurately detect and monitor Mycobacteroides abscessus lung infections. The technique uses 11C-PABA PET to differentiate between bacterial infection and inflammatory diseases.
A new PET/CT imaging technique visualizes activated fibroblasts in the heart muscle, detecting multiple forms of cardiomyopathy. The method provides valuable insights into disease progression and helps improve risk stratification for patients with non-ischemic cardiomyopathy.
A new PET radiotracer can detect a wide range of mold species linked to life-threatening infections in cancer and transplant patients. The imaging agent, 18F-FDS, has the potential to dramatically enhance diagnosis and monitoring of invasive mold infections.
A new peptide-based PET tracer outperforms FDG PET in measuring PD-L1 expression in head and neck cancers. The tracer's uptake strongly correlates with PD-L1 levels, suggesting its potential for personalized treatment strategies.
Researchers developed a novel PET tracer targeting phosphodiesterase 4B to visualize real-time brain inflammation. The tracer showed superior image quality and greater brain distribution compared to existing tracers, highlighting its potential for early diagnosis and personalized therapy in neurodegenerative diseases.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has selected 7 new Fellows for their exceptional achievements in the field. The SNMMI Fellowship is a prestigious recognition of outstanding service to the society and excellence in scientific discovery, educational efforts, or clinical practice.
A novel molecular imaging agent targeting glypican-3 has demonstrated high sensitivity and specificity in detecting hepatocellular carcinoma (HCC), including tumors smaller than one centimeter. The agent provides high-contrast images of GPC3-positive liver tumors, offering a promising new tool for early diagnosis and staging of HCC.
Researchers used PET imaging to map brain inflammation in PAOS patients, finding distinct patterns that correlate with tau pathology and Parkinson-plus syndrome. The study provides new insights into neuroinflammation's role in disease progression and may lead to earlier diagnosis and targeted treatments.
A novel integrated molecular imaging approach using dual PET/MR and PET/CMR techniques enables precise localization of heart damage and accurate identification of disease subtypes. This method also provides direct evidence supporting surgery as a cardio-protective intervention in patients with primary aldosteronism.
Cybil Nielsen has been elected as the new president of the SNMMI Technologist Section, with a focus on expanding educational programs, mentorship opportunities, and networking events. She aims to promote the recognition and advancement of nuclear medicine technologists within the healthcare landscape.
Wynn Volkert, a renowned expert in nuclear medicine, has been awarded the 2025 SNMMI Georg Charles de Hevesy Nuclear Pioneer Award. He made significant contributions to radiopharmaceutical development, including FDA-approved agents for brain and bone imaging.
A newly developed cardiac PET imaging technique offers a simpler way to detect significant coronary artery disease by eliminating the need for complex scanning protocols. The technique has been shown to accurately estimate myocardial flow reserve during both exercise and pharmacologic stress, making advanced heart imaging more accessible.
Shannon Youngblood, a seasoned nuclear medicine professional, has been elected as President-Elect of the SNMMI Technologist Section. She aims to elevate visibility and recognition for nuclear medicine professionals through advocacy, promote diversity and inclusion in the workforce, and advance education and professional development. Wi...
Julie C. Price has been recognized for her groundbreaking work on PET imaging techniques and multimodal imaging for translational neuroscience. She aims to advance early detection of Alzheimer's disease-related tau protein deposition.
A new PET imaging technique has successfully visualized three radiotracers in a single scan, enabling a more comprehensive molecular profile of disease. This innovation offers the potential to deliver greater precision in both diagnosis and therapeutic assessment, particularly for complex diseases like cancer.
A new brain imaging platform combining upright PET scanning, AR eye tracking, and motion tracking enables researchers to study brain function in a more natural and dynamic way. This approach offers a more realistic view of brain activity, holding promise for earlier detection of cognitive disorders.
Advanced software is used to measure radiation dose distribution throughout the body, ensuring patient safety and tailoring treatments. Post-therapy imaging helps identify complications and guide clinical decisions, ultimately optimizing treatment outcomes and protecting patients.
Two new PET imaging agents have been developed to identify the histamine H3 receptor, which regulates learning, memory, and sleep. These novel tracers show high brain uptake, excellent specificity, and improved in vivo stability.
Researchers found that low blood flow at rest may predict heart failure or death, while low stress flow may indicate heart attack risk. A new PET scan method also showed promise for Alzheimer's detection with high accuracy and minimal discomfort.
A novel immuno-PET/CT imaging technique has identified a potent biomarker for nasopharyngeal cancer (NPC), CD70, which is highly expressed in NPCs. The technique showed 100% detection rate of primary tumors and 93% detection rate of local lymph node metastasis in patients with early-stage disease.
New radioimmunotherapy approaches show promise against advanced breast cancer and prostate cancer. Additionally, new imaging tools enhance cancer detection and diagnosis, while a proposed standard improves lesion interpretation. Cost-effectiveness studies also support novel therapies for rare digestive cancers.
A newly developed molecular imaging technique can identify multiple subtypes of triple-negative breast cancer, improving diagnostic capacity. The approach targets extra domain A of fibronectin, a stable protein in the tumor stromal environment abundantly expressed in breast cancer.
Researchers studied obesity's impact on breast cancer, linked imaging patterns to lung disease survival, and tracked hidden inflammation in COVID-19 patients using advanced PET imaging techniques.
New studies explore peptide receptor radionuclide therapy, targeted radiation for prostate cancer, and neuroendocrine tumor treatment. Targeted radiation boosts survival in colorectal liver cancer and bone metastases, while a new PET imaging tracer shows promise for detection.
Scientists have developed a novel pretargeting system to boost cancer imaging using DARPin G3, which achieves specific tumor targeting with reduced kidney and liver uptake. GRPR is emerging as a powerful tool for both imaging and treatment in various cancers, offering personalized cancer care across multiple tumor types.
Scientists have developed a new PET imaging compound to visualize key enzymes in mental health, enabling multiple same-day scans. Additionally, researchers have discovered that PET scans can detect not only HER2-positive but also HER2-low breast cancer lesions.
Researchers have developed new imaging tools to visualize protein changes in Alzheimer's, heart and lung issues in long COVID patients, and a common marker in nasopharyngeal cancer. A first-in-human trial tests a next-generation radiopharmaceutical for advanced prostate cancer.
Researchers developed a new method for imaging enzyme activity in whole organs with high-resolution 3D mapping. This allowed them to visualize differences in aminopeptidase N activity and the effects of inhibitors in mouse kidneys. The study opens up an unbiased evaluation method for drug development.
A Phase II trial found durable antitumor activity in patients with BRCA1/2 mutations treated with olaparib and pembrolizumab, with 8.3% complete response rate
Researchers have discovered important differences in how a targeted therapy behaves in the body over time, allowing for more tailored treatment strategies. A new PET/CT scanner also shows promise for accurate imaging with dramatically reduced exposure, especially for sensitive patients like children or those needing repeated scans.
The breakthrough allows researchers to non-invasively assess BBB permeability using a wide range of radiotracers, enabling early detection of altered permeability and potential markers for neurodegenerative diseases. The scanner can also measure the effects of aging and liver inflammation on BBB health.
Researchers have developed a new method that uses expansion microscopy to overcome the spatial resolution problem in mass spectrometry imaging. This allows scientists to detect hundreds of biomolecules at the single cell level in their native locations, enabling better understanding of their functions and interactions.
Researchers have developed novel imaging agents targeting shared proteins in triple-negative breast cancer tumors, successfully highlighting various tumor types using PET/CT scans. Additionally, a new brain imaging technique shows promise in identifying complex brain diseases like progressive supranuclear palsy and corticobasal degener...
A novel radiolabeled antibody targeting the cancer antigen IL13Rα2 has been developed with high specificity for diagnosing and treating solid tumors. The antibody was effective in delineating malignancies at a low injected mass dose, making it a potential candidate for radioimmunotherapy applications.
A new microscopy technique, SIMIP, combines structured illumination with mid-infrared photothermal detection to achieve high-speed chemical imaging with superior resolution. The method outperforms conventional methods in terms of spatial resolution and chemical contrast.